Innate Pharma Shares Rise After Breakthrough Therapy Designation for Lacutamab

Dow Jones
02-18
 

By Chris Wack

 

Innate Pharma shares were up 16% to $2.25 after the company said the Food and Drug Administration has granted Breakthrough Therapy Designation to lacutamab for the treatment of adult patients with relapsed or refractory Sezary Syndrome.

The company said the designation is granted based on Phase 1 study results as well as results from a Phase 2 where lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sezary syndrome.

Sezary Syndrome is a type of skin cancer that affects white blood cells called T lymphocytes.

A Breakthrough Therapy Designation by the FDA is intended to accelerate the development and regulatory review in the U.S. of drugs that are intended to treat a serious condition and that have shown encouraging early clinical results, which may demonstrate substantial improvement on a clinically significant endpoint over available medicines.

Lacutamab previously received a Fast Track designation by the FDA in 2019 for the treatment of adult patients with relapsed or refractory Sezary syndrome who have received at least two prior systemic therapies, as well as a PRIME designation by European Medicines Agency in 2020.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

February 18, 2025 09:53 ET (14:53 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10